首页> 外国专利> Orthogonal manner Purification of Recombinant Human Parathyroid Hormone (rhPTH) (1-34)

Orthogonal manner Purification of Recombinant Human Parathyroid Hormone (rhPTH) (1-34)

机译:正交方式纯化重组人甲状旁腺激素(rhPTH)(1-34)

摘要

1. A method for the synthesis of rhPTH (1-34), comprising: i) Construction of cDNA encoding the chimeric nucleotide ORF, as specified in SEQ. ID NO.:1, by amplifying the cDNA by RT-PCR using gene-specific primers selected from SEQ. ID NO.:3, SEQ. ID NO.:4, SEQ. ID NO.:5, SEQ. ID NO.:6, SEQ. ID NO.:7 and SEQ. ID NO.:8, encoding rhPTH (1-34) chimeric fusion protein as specified in SEQ. ID NO. 2! ii) Expression of the chimeric fusion protein in presence of lactose as an inducer in the range of about 10-30% total protein! iii) purification of rhPTH (1-34), obtained with an orthogonal fashion, wherein the purification is carried out by cation exchange chromatography to a purity 98%, optionally followed by hydrophobic interaction chromatography (HIC) or RP-HPLC to a purity 99%. ! 2. The method of claim 1, wherein the expression vector containing the nucleotide ORF as indicated in SEQ. ID NO.:1, selected from the group consisting of pLMab, pRA, pET19b, wherein the vector is a pET 19b. ! 3. The method of claim 1, wherein the synthesis of a fusion nucleotide ORF, as specified in SEQ. ID NO.:1, is under the control of an inducible promoter selected from the group consisting of araBAD, trp, T7, lac, Pho and trc, preferably T7 promoter. ! 4. The method of claim 1, wherein the chimeric fusion partner consists essentially of 41 amino acid peptide of β-galactosidase (LacZ) Escherichia coli. ! 5. The method of claim 1, wherein the hybrid fusion protein as specified in SEQ. ID. No.:2, it consists of affine end (affinity handle) selected from the group consisting of a polyhistidine-tag, GST tag, protein and lactose binding staphylococcal protein, wherein the affinity tag is a polyhistidine-tag. ! 6. The method of claim 1, wherein the RP-HPLC column selected from the group consisting of C4, C8 and C18, wherein the column is a C4. ! 7.
机译:1.一种合成rhPTH(1-34)的方法,其包括:i)构建编码SEQ ID NO:1中指定的嵌合核苷酸ORF的cDNA。 ID号:1,通过使用选自SEQ.ID.No.1的基因特异性引物通过RT-PCR扩增cDNA。编号:3,SEQ.ID.No。:3。编号:4,SEQ.ID.No。:4。编号:5,SEQ.ID.No。:5。编号:6,SEQ.ID.No。:6。编号:7和SEQ。编码SEQ ID NO:8的rhPTH(1-34)嵌合融合蛋白的ID NO.:8。证件号码。 2! ii)嵌合融合蛋白在作为诱导剂的乳糖存在下的表达为总蛋白的约10-30%! iii)以正交方式纯化rhPTH(1-34),其中纯化是通过阳离子交换色谱法进行的,其纯度> 98%,然后可选地通过疏水相互作用色谱法(HIC)或RP-HPLC进行纯化> 99%。 ! 2.如权利要求1所述的方法,其特征在于,所述表达载体包含SEQ ID NO:1所示的核苷酸ORF。 ID NO.:1,选自pLMab,pRA,pET19b,其中载体是pET 19b。 ! 3.如权利要求1所述的方法,其特征在于,如SEQ.ID.No.1所示合成融合核苷酸ORF。 ID NO.:1在选自araBAD,trp,T7,lac,Pho和trc的诱导型启动子的控制下,优选T7启动子。 ! 4.权利要求1的方法,其中所述嵌合融合伴侣基本上由β-半乳糖苷酶(LacZ)大肠杆菌的41个氨基酸的肽组成。 ! 5.权利要求1的方法,其中SEQ ID NO:1中指定的杂合融合蛋白为SEQ.ID.No.1。 ID。 No.:2,其由选自多组氨酸标签,GST标签,蛋白质和结合乳糖的葡萄球菌蛋白组成的组的仿射末端(亲和柄)组成,其中所述亲和标签是多组氨酸标签。 ! 6.权利要求1的方法,其中所述RP-HPLC柱选自C4,C8和C18,其中所述柱是C4。 ! 7。

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号